EFFECTS OF CLOFIBRATE ON PLASMA-LIPIDS AND HIGH-DENSITY LIPOPROTEIN LEVELS IN RENAL-ALLOGRAFT RECIPIENTS

  • 1 January 1979
    • journal article
    • research article
    • Vol. 12  (2) , 83-86
Abstract
Successfully transplanted renal patients (13) with normal and elevated plasma lipids were treated as out-patients for 2 mo. intervals with placebo and clofibrate (2 g/day) and whole plasma and lipoprotein triglyceride and cholesterol concentrations were measured. With clofibrate treatment, plasma triglyceride (194 .+-. 11 to 157 .+-. 10 mg/100 ml; P < 0.01) and cholesterol (242 .+-. 8 to 212 .+-. 8 mg/100 ml; P < 0.002) concentrations both decreased significantly despite the continued administration of stable immunosuppressive doses of prednisolone. While the absolute changes in cholesterol in the low and high-density lipoprotein classes varied considerably following clofibrate administration, the ratio of cholesterol in the low and high-density lipoproteins fell from 3.8 to 3.3. This theoretically beneficial anti-atherogenic effect was significant (P < 0.01) in male allograft recipients only. Clofibrate treatment favorably influences the cardiovascular risk posed by both qualitative and quantitative disturbances in lipoprotein transport following successful renal allografting.